Zobrazeno 31 - 38
of 38
pro vyhledávání: ''
Publikováno v:
The oncologist. 23(6)
Background Pazopanib is an oral tyrosine-kinase inhibitor that is approved by the U.S. Food and Drug Administration for treatment of metastatic renal cell carcinoma (mRCC). Pharmacokinetic data have shown that concomitant administration of pazopanib
Publikováno v:
Oncologist
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Background Daratumumab (a human CD38-directed monoclonal antibody) and pomalidomide (an immunomodulatory drug) plus dexamethasone are both relatively new treatment options for patients with heavily pretreated multiple myeloma. A matching adjusted ind
Autor:
Wen Xia, Huimin Yuan, Qianyi Lu, Shusen Wang, Kaping Lee, Yanxia Shi, Jingmin Zhang, Fei Xu, Zhongyu Yuan
Publikováno v:
The Oncologist
Lessons Learned Studies targeting the androgen receptor (AR) signaling pathway in aromatase inhibitor (AI)-resistant breast cancer are limited. Bicalutamide, one of the commonly used AR inhibitors in prostate cancer, in combination with AI, did not s
Autor:
Anas Al-Janadi, Muhammad Usman, J. Paul Monk, Daniel Silbiger, Lance K. Heilbrun, Arif Hussain, Thomas W. Flaig, S. Percy Ivy, Susan Bolton, Primo N. Lara, Philip J. Stella, Daryn Smith, Ulka N. Vaishampayan, Elisabeth I. Heath, Glenn Liu, Philip C. Mack, Heather D. Mannuel, Amado J. Zurita
Publikováno v:
The Oncologist
Lessons Learned The negative results are consistent with the negative results of large phase III trials in which docetaxel plus antiangiogenic agents were used in patients with metastatic castrate-resistant prostate cancer (mCRPC). The negative data
Autor:
Anders Ullén, Fredrik Jäderling, Per Grybäck, Mads Agerbæk, Helle Pappot, Jeffrey Yachnin, C.-H. Shah, H. Von Der Maase, Karin Holmsten
Publikováno v:
Shah, C H, Pappot, H, Agerbæk, M, Holmsten, K, Jäderling, F, Yachnin, J, Grybäck, P, von der Maase, H & Ullén, A 2019, ' Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor) : Phase I Trial ', Oncologist, vol. 24, no. 6, pp. 745-e213 . https://doi.org/10.1634/theoncologist.2018-0795
The Oncologist
The Oncologist
Lessons Learned First trial to report safety and activity of the microtubule inhibitor vinflunine plus the tyrosine kinase inhibitor sorafenib in post-platinum metastatic urothelial cancer (mUC) patients. A recommended phase II dose was identified fo
Autor:
Jeremy O. Jones, Josiah Hawks, David Gill, Gayatri Nachaegari, Robert A. Stephenson, Julia A. Batten, Christopher Dechet, Meghan Salgia, Christopher Martin, Roberto Nussenzveig, Sumanta K. Pal, William T. Lowrance, Ting Liu, Neeraj Agarwal, Benjamin L. Maughan, Kenneth M. Boucher
Publikováno v:
The Oncologist
Lessons Learned Pazopanib was not effective in altering the premetastatic niche in the neoadjuvant setting. Pazopanib was safe and well tolerated without any new safety signals. Background Vascular endothelial growth factor receptor 1 (VEGFR1) expres
Autor:
Ghassan K. Abou-Alfa, Rebecca A. Miksad, Martin Gutierrez, Matthew L. Sherman, Olugbenga Olowokure, Manish R. Sharma, Imane El Dika, Shuchi Sumant Pandya, Stephen K. Williamson, Mohamedtaki Abdulaziz Tejani
Publikováno v:
Ann Transl Med
Lessons Learned Patients with hepatocellular carcinoma (HCC) often have limited therapeutic responses to the vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor sorafenib, which is standard of care in advanced HCC. Targeting the activ
Autor:
Alberto Chiappori, Taher Abu Hejleh, Jorge Nieva, Christine L. Hann, Michael J. Schell, Taofeek K. Owonikoko, Anne M. Traynor, Afshin Dowlati, Xiuhua Zhao, Leora Horn, Gregory A. Otterson, Daniel M. Sullivan, Helen J. Ross
Publikováno v:
The Oncologist
Lessons Learned Targeted therapy options for SCLC patients are limited; no agent, thus far, has resulted in a strategy promising enough to progress to phase III trials. Linsitinib, a potent insulin growth factor-1-receptor tyrosine kinase inhibitor,
- [1]
- « Předchozí
- 1
- 2
- 3
- 4